Nonetheless, in vivo, CD19@NP accumulated in lymphoid organs (e.g., bone marrow, spleen, lymph nodes) and blood-rich organs (e.g., liver), indicating effective targeting for immune and hematological diseases such as leukemia or lymphoma. This evidence concerns the gene CD19 and lymphoma.